Treatment with akebia saponin D ameliorates Aβ1-42-induced memory impairment and neurotoxicity in rats

Molecules

Volumn 21, Issue 3, 2016, Pages

  Chen, Yongde ^a   Yang, Xiaolin ^b   Chen, Tong ^a   Ji, Jing ^a   Lan, Li ^a   Hu, Rong ^a   Ji, Hui ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Akebia saponin D (ASD); Alzheimer's disease; Amyloid (A )1 42; Cognitive impairment; Neurotoxicity

Indexed keywords

EID: 84963999534     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules21030323     Document Type: Conference Paper

References (46)

1. Mueller, S.G.; Dickerson, B.C. Atrophy accelerates with conversion from mild cognitive impairment to Alzheimer disease. Neurology 2008, 70, 1728-1729. [CrossRef] [PubMed]
2. Querfurth, H.W.; LaFerla, F.M. Alzheimer's disease. N. Engl. Med. 2010, 362, 329-344. [CrossRef] [PubMed]
3. Terry, A.V., Jr.; Callahan, P.M.; Hall, B.;Webster, S.J. Alzheimer's disease and age-related memory decline (preclinical). Pharmacol. Biochem. Behav. 2011, 99, 190-210. [CrossRef] [PubMed]
4. Bero, A.W.; Bauer, A.Q.; Stewart, F.R.; White, B.R.; Cirrito, J.R.; Raichle, M.E.; Culver, J.P.; Holtzman, D.M. Bidirectional relationship between functional connectivity and amyloid-beta deposition in mouse brain. J. Neurosci. 2012, 32, 4334-4340. [CrossRef] [PubMed]
5. Mandelkow, E.M.; Mandelkow, E. Tau in Alzheimer's disease. Trends Cell Biol. 1998, 8, 425-427. [CrossRef]
6. Cole, S.L.; Vassar, R. The role of amyloid precursor protein processing by bace1, the beta-secretase, in Alzheimer disease pathophysiology. J. Biol. Chem. 2008, 283, 29621-29625. [CrossRef] [PubMed]
7. Vahidi, A.; Glenn, G.; van der Geer, P. Identification and mutagenesis of the tace and gamma-secretase cleavage sites in the colony-stimulating factor 1 receptor. Biochem. Biophys. Res. Commun. 2014, 450, 782-787. [CrossRef] [PubMed]
8. Wang, Q.; Li, H. Research on regulation function of gamma-secretase inhibitor dapt on the differentiation of neural precursor cell line. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 2015, 32, 126-130. [PubMed]
9. Del Turco, D.; Schlaudraff, J.; Bonin, M.; Deller, T. Upregulation of APP, ADAM10 and ADAM17 in the denervated mouse dentate gyrus. PLoS ONE 2014, 9, e84962. [CrossRef] [PubMed]
10. Bernstein, H.G.; Stricker, R.; Lendeckel, U.; Bertram, I.; Dobrowolny, H.; Steiner, J.; Bogerts, B.; Reiser, G. Reduced neuronal co-localisation of nardilysin and the putative α-secretases ADAM10 and ADAM17 in Alzheimer's disease and down syndrome brains. AGE 2009, 31, 11-25. [CrossRef] [PubMed]
11. Hartl, D.; Klatt, S.; Roch, M.; Konthur, Z.; Klose, J.; Willnow, T.E.; Rohe, M. Soluble Alpha-APP (sAPPalpha) regulates CDK5 expression and activity in neurons. PLoS ONE 2013, 8, e65920. [CrossRef] [PubMed]
12. Guan, H.; Chow, K.M.; Shah, R.; Rhodes, C.J.; Hersh, L.B. Degradation of islet amyloid polypeptide by neprilysin. Diabetologia 2012, 55, 2989-2998. [CrossRef] [PubMed]
13. Kakiya, N.; Saito, T.; Nilsson, P.; Matsuba, Y.; Tsubuki, S.; Takei, N.; Nawa, H.; Saido, T.C. Cell surface expression of the major amyloid-βpeptide (Aβ)-degrading enzyme, neprilysin, depends on phosphorylation by mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (mek) and dephosphorylation by protein phosphatase 1a. J. Biol. Chem. 2012, 287, 29362-29372. [CrossRef] [PubMed]
14. Carrasquillo, M.M.; Belbin, O.; Zou, F.; Allen, M.; Ertekin-Taner, N.; Ansari, M.; Wilcox, S.L.; Kashino, M.R.; Ma, L.; Younkin, L.H.; et al. Concordant association of insulin degrading enzyme gene (IDE) variants with IDE mRNA, Aβ, and Alzheimer's Disease. PLoS ONE 2010, 5, e8764. [CrossRef] [PubMed]
15. Leal, M.C.; Magnani, N.; Villordo, S.; Buslje, C.M.; Evelson, P.; Castano, E.M.; Morelli, L. Transcriptional regulation of insulin-degrading enzyme modulates mitochondrial amyloid β (Aβ) peptide catabolism and functionality. J. Biol. Chem. 2013, 288, 12920-12931. [CrossRef] [PubMed]
16. Pacheco-Quinto, J.; Herdt, A.; Eckman, C.B.; Eckman, E.A. Endothelin-converting enzymes and related metalloproteases in Alzheimer's disease. J. Alzheimers Dis. 2013, 33, S101-S110. [PubMed]
17. Wang, R.; Wang, S.; Malter, J.S.; Wang, D.S. Effects of 4-hydroxy-nonenal and amyloid-β on expression and activity of endothelin converting enzyme and insulin degrading enzyme in SH-SY5Y cells. J. Alzheimers Dis. 2009, 17, 489-501. [PubMed]
18. Vepsalainen, S.; Hiltunen, M.; Helisalmi, S.; Wang, J.; van Groen, T.; Tanila, H.; Soininen, H. Increased expression of Aβ degrading enzyme IDE in the cortex of transgenic mice with Alzheimer's disease-like neuropathology. Neurosci. Lett. 2008, 438, 216-220. [CrossRef] [PubMed]
19. Leissring, M.A.; Farris,W.; Chang, A.Y.;Walsh, D.M.;Wu, X.; Sun, X.; Frosch, M.P.; Selkoe, D.J. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 2003, 40, 1087-1093. [CrossRef]
20. Walsh, D.M.; Thulin, E.; Minogue, A.M.; Gustavsson, N.; Pang, E.; Teplow, D.B.; Linse, S. A facile method for expression and purification of the Alzheimer's disease-associated amyloid β-peptide. FEBS J. 2009, 276, 1266-1281. [CrossRef] [PubMed]
21. Folch, J.; Ettcheto, M.; Petrov, D.; Abad, S.; Pedros, I.; Marin, M.; Olloquequi, J.; Camins, A. Review of the advances in treatment for Alzheimer disease: Strategies for combating β-amyloid protein. Neurologia 2015. [CrossRef]
22. Schenk, D.; Basi, G.S.; Pangalos, M.N. Treatment strategies targeting amyloid beta-protein. Cold Spring Harb. Perspect. Med. 2012, 2, a006387. [CrossRef] [PubMed]
23. Schwartz, A. What's next for alzheimer treatment?: While Aβ isn't out of the picture yet, several other therapeutic routes are being explored. Ann. Neurol. 2013, 73, A7-A9. [CrossRef] [PubMed]
24. Ginty, D.D.; Bonni, A.; Greenberg, M.E. Nerve growth factor activates a Ras-dependent protein kinase that stimulates c-fos transcription via phosphorylation of CREB. Cell 1994, 77, 713-725. [CrossRef]
25. Hung, T.M.; Na, M.; Thuong, P.T.; Su, N.D.; Sok, D.; Song, K.S.; Seong, Y.H.; Bae, K. Antioxidant activity of caffeoyl quinic acid derivatives from the roots of dipsacus asper wall. J. Ethnopharmacol. 2006, 108, 188-192. [CrossRef] [PubMed]
26. Jung, K.Y.; Do, J.C.; Son, K.H. Triterpene glycosides from the roots of dipsacus asper. J. Nat. Prod. 1993, 56, 1912-1916. [CrossRef] [PubMed]
27. Kim, B.S.; Kim, Y.C.; Zadeh, H.; Park, Y.J.; Pi, S.H.; Shin, H.S.; You, H.K. Effects of the dichloromethane fraction of Dipsaci Radix on the osteoblastic differentiation of human alveolar bone marrow-derived mesenchymal stem cells. Biosci. Biotechnol. Biochem. 2011, 75, 13-19. [CrossRef] [PubMed]
28. Niu, Y.; Li, Y.; Huang, H.; Kong, X.; Zhang, R.; Liu, L.; Sun, Y.;Wang, T.; Mei, Q. Asperosaponin VI, a saponin component from Dipsacus asper wall, induces osteoblast differentiation through bone morphogenetic protein-2/p38 and extracellular signal-regulated kinase 1/2 pathway. Phytother. Res. 2011, 25, 1700-1706. [CrossRef] [PubMed]
29. Wang, Y.; Wang, X.X.; Zhang, L.N.; Jin, S.M.; Zhang, J. Effects of traditional chinese medicine on bone remodeling during orthodontic tooth movement. J. Ethnopharmacol. 2012, 141, 642-646. [CrossRef] [PubMed]
30. Zhang, Z.J.; Qian, Y.H.; Hu, H.T.; Yang, J.; Yang, G.D. The herbal medicine dipsacus asper wall extract reduces the cognitive deficits and overexpression of β-amyloid protein induced by aluminum exposure. Life Sci. 2003, 73, 2443-2454. [CrossRef]
31. Zhou, Y.Q.; Yang, Z.L.; Xu, L.; Li, P.; Hu, Y.Z. Akebia saponin D, a saponin component from Dipsacus asper wall, protects PC 12 cells against amyloid-beta induced cytotoxicity. Cell Biol. Int. 2009, 33, 1102-1110. [CrossRef] [PubMed]
32. Russo, I.; Caracciolo, L.; Tweedie, D.; Choi, S.H.; Greig, N.H.; Barlati, S.; Bosetti, F. 3,6'-dithiothalidomide, a new TNF-α synthesis inhibitor, attenuates the effect of Aβ-42 intracerebroventricular injection on hippocampal neurogenesis and memory deficit. J. Neurochem. 2012, 122, 1181-1192. [CrossRef] [PubMed]
33. Yu, X.;Wang, L.N.; Du, Q.M.; Ma, L.; Chen, L.; You, R.; Liu, L.; Ling, J.J.; Yang, Z.L.; Ji, H. Akebia saponin d attenuates amyloid β-induced cognitive deficits and inflammatory response in rats: Involvement of akt/nf-kappab pathway. Benav. Brain Res. 2012, 235, 200-209. [CrossRef] [PubMed]
34. Cummings, J.L.; Geldmacher, D.; Farlow, M.; Sabbagh, M.; Christensen, D.; Betz, P.; Grp, D.M.E.W. High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: Drug profile and clinical guidelines. CNS Neurosci. Ther. 2013, 19, 294-301. [CrossRef] [PubMed]
35. Ye, C.Y.; Lei, Y.; Tang, X.C.; Zhang, H.Y. Donepezil attenuates abeta-associated mitochondrial dysfunction and reduces mitochondrial abeta accumulation in vivo and in vitro. Neuropharmacology 2015, 95, 29-36. [CrossRef] [PubMed]
36. Shi, J.; Liu, Q.; Wang, Y.; Luo, G. Coadministration of huperzine a and ligustrazine phosphate effectively reverses scopolamine-induced amnesia in rats. Pharmacol. Biochem. Behav. 2010, 96, 449-453. [CrossRef] [PubMed]
37. Vorhees, C.V.; Williams, M.T. Morris water maze: Procedures for assessing spatial and related forms of learning and memory. Nat. Protoc. 2006, 1, 848-858. [CrossRef] [PubMed]
38. Glenner, G.G.; Wong, C.W. Alzheimer's Disease and down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 1984, 122, 1131-1135. [CrossRef]
39. Olkhov, V.K.; Rayburn, S.N. Leading-Edge Research in Alzheimer's Disease; Nova Science Publishers: Hauppauge, NY, USA, 2008; pp. 125-131.
40. Candore, G.; Bulati, M.; Caruso, C.; Castiglia, L.; Colonna-Romano, G.; di Bona, D.; Duro, G.; Lio, D.; Matranga, D.; Pellicano, M.; et al. Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in alzheimer disease: Therapeutic implications. Rejuv. Res. 2010, 13, 301-313. [CrossRef] [PubMed]
41. Abdi, A.; Sadraie, H.; Dargahi, L.; Khalaj, L.; Ahmadiani, A. Apoptosis inhibition can be threatening in Aβ-induced neuroinflammation, through promoting cell proliferation. Neurochem. Res. 2011, 36, 39-48. [CrossRef] [PubMed]
42. Sclip, A.; Tozzi, A.; Abaza, A.; Cardinetti, D.; Colombo, I.; Calabresi, P.; Salmona, M.;Welker, E.; Borsello, T. C-Jun N-terminal kinase has a key role in Alzheimer disease synaptic dysfunction in vivo. Cell Death. Dis. 2014, 5, e1019. [CrossRef] [PubMed]
43. Zeng, Y.; Zhao, D.; Xie, C.W. Neurotrophins enhance camkii activity and rescue amyloid-beta-induced deficits in hippocampal synaptic plasticity. J. Alzheimers Dis. 2010, 21, 823-831. [PubMed]
44. Gao, C.; Liu, Y.; Jiang, Y.; Ding, J.; Li, L. Geniposide ameliorates learning memory deficits, reduces tau phosphorylation and decreases apoptosis via GSK3β pathway in streptozotocin-induced alzheimer rat model. Brain Pathol. 2014, 24, 261-269. [CrossRef] [PubMed]
45. Hamdane, M.; Delobel, P.; Sambo, A.V.; Smet, C.; Begard, S.; Violleau, A.; Landrieu, I.; Delacourte, A.; Lippens, G.; Flament, S.; et al. Neurofibrillary degeneration of the Alzheimer-type: an alternate pathway to neuronal apoptosis? Biochem. Pharmacol. 2003, 66, 1619-1625. [CrossRef]
46. Kostylev, M.A.; Kaufman, A.C.; Nygaard, H.B.; Patel, P.; Haas, L.T.; Gunther, E.C.; Vortmeyer, A.; Strittmatter, S.M. Prion-protein-interacting amyloid-beta oligomers of high molecular weight are tightly correlated with memory impairment in multiple Alzheimer mouse models. J. Biol. Chem. 2015, 290, 17415-17438. [CrossRef] [PubMed]